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The human placenta nourishes and protects the developing foetus whilst influencing mater-
nal physiology for fetal advantage. It expresses several members of the vascular endothelial
growth factor (VEGF) family including the pro-angiogenic/pro-permeability VEGF-A165a iso-
form, the anti-angiogenic VEGF-A165b, placental growth factor (PIGF) and their receptors,
VEGFR1 and VEGFR2. Alterations in the ratio of these factors during gestation and in com-
plicated pregnancies have been reported; however, the impact of this on feto-placental en-
dothelial barrier integrity is unknown. The present study investigated the interplay of these
factors on junctional occupancy of VE-cadherin and macromolecular leakage in human en-
dothelial monolayers and the perfused placental microvascular bed. Whilst VEGF-A165a
(50 ng/ml) increased endothelial monolayer albumin permeability (P<0.0001), equimolar
concentrations of VEGF-A165b (P>0.05) or PlGF (P>0.05) did not. Moreover, VEGF-A165b
(100 ng/ml; P<0.001) but not PlGF (100 ng/ml; P>0.05) inhibited VEGF-A165a-induced
permeability when added singly. PlGF abolished the VEGF-A165b-induced reduction in
VEGF-A165a-mediated permeability (P>0.05); PlGF was found to compete with VEGF-A165b
for binding to Flt-1 at equimolar affinity. Junctional occupancy of VE-cadherin matched al-
terations in permeability. In the perfused microvascular bed, VEGF-A165b did not induce
microvascular leakage but inhibited and reversed VEGF-A165a-induced loss of junctional
VE-cadherin and tracer leakage. These results indicate that the anti-angiogenic VEGF-A165b
isoform does not increase permeability in human placental microvessels or HUVEC primary
cells and can interrupt VEGF-A165a-induced permeability. Moreover, the interplay of these
isoforms with PIGF (and s-flt1) suggests that the ratio of these three factors may be impor-
tant in determining the placental and endothelial barrier in normal and complicated preg-
nancies.
Introduction
The human placenta is a fetal organ which allows oxygen and selective nutrient uptake from the mother
to the fetus, whilst acting as a discriminatory barrier. It does this by having a unique architecture, spe-
cific to human and macaque monkeys, where the placental microvessels, encased in a single layer of
syncytiotrophoblast, lie bathed in maternal blood (haemomonochorial). fetal blood enters these vessels
through the umbilical arteries and returns replenished via the umbilical vein. Both the thin outer syncy-
tial lining and the fetal endothelium act as resistance in series to transport of hydrophilic solutes from
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maternal to fetal blood [1]. The feto-placental endothelial barrier integrity is therefore of critical importance to fetal
growth and well-being.
The placental endothelium is continuous, with well-defined cell–cell junctions that restrict movement of large hy-
drophilic molecules (>65 kDa) across the paracellular cleft [2]. Adherens junctions (AJs) are the major regulators
of paracellular permeability in the placental capillaries with the transmembrane adhesion molecule – vascular en-
dothelial (VE)-cadherin being the key player [3-5]. Phosphorylation of VE-cadherin leads to breakage of homophilic
binding, loss of anchorage to peri-junctional actin and translocation from AJ domains with accompanying increases
in paracellular cleft dimensions and increased paracellular permeability [6]. VEGF-A, via stimulation of VEGFR2,
has been shown to increase phosphorylation of VE-cadherin at Tyr-685 and Tyr-731 facilitating increased solute
permeability and extravasation of cells [7].
The human placenta expresses the pro-angiogenic/pro-permeability VEGF-A165a, anti-angiogenic VEGF-A165b,
placental growth factor (PIGF) and their receptors, VEGFR2 (KDR), VEGFR1 (Flt-1), neuropilin-1 and soluble
Flt-1 (sFlt-1). There is differential expression of the growth factors during gestation and in complicated pregnan-
cies. VEGF-A levels are highest in the first trimester during de novo synthesis of placental vessels [8,9]). The in
situ location also alters with gestation; in the last trimester VEGF-A is found predominantly in the terminal villi
which house dilated fetal capillary loops involved in materno-fetal exchange [10]. Elevated levels of VEGF-A, loss of
junctional VE-cadherin and increased vascular leakage have been reported in pregnancies complicated by maternal
diabetes ([11,12]) whilst trophoblast derived factors from pre-eclamptic placenta have been shown to diminish bar-
rier function and alter VE-cadherin distribution in vitro [13]. The anti-angiogenic splice variant VEGF-A165b has
been shown to be present in human term placentae as a small part of the total VEGF expression. Interestingly, there
is a further down-regulation of this in pre-eclamptic placenta [14]. Whether this splice-variant can affect placental
vascular permeability is not known.
PIGF, a homologue of VEGF [15], rises steadily until the second trimester of pregnancy – a period of maximal
vessel maturation and then begins to fall [16]. Lower PIGF levels in maternal circulation have been correlated with
small-for-gestational-age babies in normal pregnancies [17,18]. A down-regulation of syncytiotrophoblast PlGF was
found in pre-eclamptic placenta [19]. Its function in the placenta remains to be shown experimentally. Of the various
isoforms of PIGF, PIGF-2 is thought to enhance VEGF-induced permeability, whilst PIGF promotes VEGF-induced
angiogenesis in some models and antagonizes in others [20,15]).
The interplay of VEGF-A165a, VEGF-A165b and PIGF depend largely on their interactions with their receptors
and co-receptors. VEGF-A165a is able to bind to both VEGFR1 and R2 but acts mainly via the latter [21]. Interest-
ingly, neuropilin-1 can complex with VEGFR1 and R2 and has been shown to potentiate VEGFR2 activation [22].
VEGF-A165b binds to both VEGFR1 and R2 receptors but is a weaker agonist for VEGFR2 [23]. VEGF-A165b differs
from VEGF-A165a only in the last six amino acids, the residues necessary for interaction with neuropilin-1, [24-26]
and this lack of co-receptor binding may be behind its function as a partial receptor agonist. PlGF only binds to
VEGFR1 but has been shown to propagate kinase cascades for VE-cadherin autophosphorylation [27]. The compet-
itive interplay between the VEGF splice variants and PIGF in regulation of human placental endothelial junctional
integrity requires elucidation.
The aim of the present study was therefore to investigate whether VEGF-A165a, VEGF-A165b and PlGF, singly or
in combination can affect junctional occupancy of VE-cadherin and alter paracellular permeability of human pla-
cental/fetal endothelium. Term placenta and umbilical cord from healthy pregnancies were used for ex vivo placental
perfusion experiments and for endothelial primary cell culture studies. Results obtained will advance understanding
of the mechanisms employed by the human placenta for maintenance of the feto-placental endothelial barrier and
how this could be perturbed in complicated pregnancies.
Methodology
Placenta and umbilical cord collection
Term placentas and umbilical cords were obtained at elective caesarean section from normal pregnancies with in-
formed patient consent and full ethical approval (REC Ref 14/SC/ 1194; NHS Heath Research Authority, U.K.), and
permission from Nottingham University Hospitals, NHS Trust, U.K. The work described here has been carried out
in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).
All term placentas and umbilical cords were obtained from term (≥37 weeks), non-labouring women (Table 1)
undergoing scheduled elective caesarean section delivery. Indications for caesarean section include maternal re-
quest, breech presentation, and previous caesarean section.Womenwith pre-existing conditions such as hypertension
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Table 1 The characteristics of patients undergoing caesarean deliveries who participated in the present study, and whose
data were used for further analysis
Age (years) 29.5 +− 4.7
BMI 25.6 +− 2.4
Parity 2 [2–3]
Gestational age (weeks) 40.6 +− 3.5




Weight of offspring (kg) 3.3 +− 0.6
BMI, body mass index; data reported as mean +− the standard deviation (SD), median [Interquartile range (IQR)], or percentage of offspring.
(>140/90mmHg), proteinuria, diabetes, gestational diabetes, renal and cardiac disease, and other conditions thatmay
compromise patient health were excluded. Smokers were excluded from the study.
Primary cell culture
Human umbilical vein endothelial cell (HUVECs) were isolated from freshly delivered umbilical cords and cul-
tured on 1% gelatin-coated flasks in complete endothelial cell medium M199 (Gibco), supplemented with 20% fe-
tal bovine serum (FBS), heparin sodium salt (50 μg/ml), endothelial cell growth factor supplement (50 μg/ml), and
penicillin/streptomycin (100 U/100 mg/ml), under humidified conditions at 37◦C and 5% CO2/95% air. In all exper-
iments, HUVECs were grown and used only up to the third passage.
HUVEC permeability assays
Polyester membrane transwell 6.5 mm2 inserts with a 0.4 μm pore diameter (Corning, U.K.) were coated with 1%
gelatin in 0.1 M PBS. They were suspended in a 24-well cell culture plates and seeded with 5 × 103 cells. Hundred
microlitres of complete endothelial cell medium M199 was added to the upper compartment and 400 μl added to
lower compartment to equalize hydrostatic fluid pressures. HUVECs were allowed to form a confluent monolayer
before experimentation. There were four inbuilt experimental repeats (transwell assays) per experiment. The whole
was repeated (×4) using HUVECS isolated from four different cords.
Experimental design
Medium in the upper chamber was replaced with 100 μl of dialysed (10 kDa dialysis tubing) fluorescein
isothiocyanate-conjugated bovine serum albumin (FITC-BSA, 66 kDa;Thermo Fisher) in phenol-freeM199medium
at a concentration of 1 mg/ml. After a 30-min equilibration, HUVECs were exposed to a single addition of re-
combinant human VEGF-A165a (50 ng/ml), VEGF-A165b (50 ng/ml) or PlGF (50 ng/ml). In further experiments,
VEGF-A165a (50 ng/ml) was followed by VEGF-A165b (100 ng/ml), PlGF-2 (264-PG, R&D Systems 100 ng/ml) or
both VEGF-A165b (100 ng/ml) and PlGF-2 (100 ng/ml) in combination. Fifty microlitres of samples were collected
from the lower compartment at 0, 30, 60, 90 and 120 min intervals, with the equivalent volume of fresh phenol-free
M199 medium replenished after each sample collection. Samples were diluted in 50 μl of 0.1 M PBS and measured
using a Thermo Fluoroskan Ascent F2 fluorescence plate reader at an emission/excitation wavelength of 495/520 nm.
Concentrations of FITC–albumin in each sample were calculated via linear regression of a serial dilution series of the
tracer. Total permeability of monolayers were calculated for each treatment based on the rate of solute flux (calculated
in μg/min) over the first 30 min, the surface area of the monolayer, and the initial concentration difference between
the upper and lower wells (1 mg/ml).
Immunostaining
After experimentation, monolayers were immediately fixed in 1% PFA. Cells were permeabilized with 0.15% Triton
X-100 followed by blocking with 4% normal human serum in 0.1 M PBS for 30 min at RT. Monolayers were incubated
withmouse anti-human CD144 (ThermoFisher) (VE-cadherin; 5μg/ml) overnight at 4◦C and FITC-conjugated goat
anti-mouse IgG (Sigma-Aldrich, 20 μg/ml) for 2 h at 37◦C in the dark after requisite washes.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
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Extra-corporeal perfusion of the placental microvascular bed
A well-established dual-perfusion procedure was employed [1,2,9-12]. To summarize, immediately after caesarean
delivery, the placenta was transferred to a 37◦C chamber with the umbilical cord kept clamped until cannulation to
prevent loss of blood and collapse of feto-placental vessels. Within 20 min of arrival of the placenta, a vein and an
artery supplying the microvascular bed of a randomly chosen intact cotyledon were each cannulated with a naso-
gastric (5 mm) tube to establish the fetal circulation. The placenta was inverted and the cotyledon was clamped in a
Perspex chamber to isolate the lobule from the rest of the placenta. The independent maternal circulation was simu-
lated by inserting five 5 mmnasogastric tubes into the intervillous space through the basal plate of the cotyledon, and
drained through an exit tube in the Perspex chamber. Fetal and maternal circulations were connected to peristaltic
pumps providing a constant 20 ml/min flow to the maternal circulation and a 5 ml/min flow to the fetal circulation,
replicating the physiologic flow rates seen in utero. Establishment of both circulations were completed within 30 min
of delivery to minimize hypoxic damage to the placenta. Perfusion was abandoned if fetal venous outflow was less
than arterial inflow. From the 20 intact placenta recruited for the perfusion experiments, 15 allowed full perfusion
(25% failure rate).
Experimental design
A 20-min open circuit equilibration period with oxygenated Medium 199 (Sigma, Poole, U.K.), with added sodium
bicarbonate (2.2 g/l), albumin (5 g/l), high molecular weight dextran (2000 Mr; 8 g/l) and heparin (5000 IU/l) (final
pH 7.2–7.4), was performed to reverse any post-parturition hypoxic changes [1]. After equilibration, fetal oxygenation
was discontinued and both the maternal and foetal circulations were closed. Perfusion pressures were monitored and
accepted if foetal pressure was between 40–80 mmHg and maternal pressure was between 18–20 mmHg [2].
Recombinant human VEGF-A165a (20 ng/ml), VEGF-A165b (20 ng/ml) or vehicle were introduced into the fetal
circulation and the lobules perfused for 30 min. In reversal experiments, VEGF-A165a exposure was followed by a
separate VEGF-A165b (40 ng/ml) perfusion (vehicle only acted as control) for an additional 30 min. Three differ-
ent placentas were used for each experimental exposure. Tetramethylrhodamine isothiocyanate (TRITC)-conjugated
dextran (76Mr; Sigma, Dorset, U.K.), 1 mg/ml) was added as a bolus into the fetal circulation for the last 10 min of
all perfusions (single growth factors or sequential VEGF isoform perfusions). The lobules were then perfusion fixed
with 1% paraformaldehyde in 0.1 M phosphate buffer saline (pH 7.3) for 30 min. The lobule was excised and 10 mm3
biopsies taken for a further immersion fixation (2 h). Biopsies were rinsed in PBS, cut into 5 mm3 pieces, frozen in
nitrogen-cooled isopentane (Fisher Scientific UK Limited, Loughborough, U.K.) and stored at−80◦C until required.
Immunostaining
A minimum of six different blocks (randomly chosen) per placenta were cryo-sectioned and a minimum of six sec-
tions (5 μm thick) were taken from each block at different depths. Cryo-sections were air-dried and washed in 0.1
M PBS/BSA, before permeabilization with 0.15% Triton X-100 followed by blocking with 4% normal human serum
in 0.1 M PBS for 30 min at room temperature. Sections were incubated overnight with mouse anti-human CD144
(VE-cadherin; 5 μg/ml) at 4◦C and secondary antibodies as described before.
Microscopy and analysis
Transwell membranes and placental sections were visualized for expression of CD144 and TRITC-Dextran tracer
using a Nikon LaboPhot-2 fluorescence microscope (Nikon, U.K.) and appropriate TRITC/FITC filters. Images (ob-
tained by systematic random sampling of entire sections or membranes) from both channels were acquired using a
Nikon Coolpix 995 camera (Nikon, U.K.).
Junctional integrity and tracer leakage analysis
Micrographs were analysed using Adobe Photoshop 6.0 (Adobe systems, U.K.). A pre-determined electronic grid
was placed over each image and both VE-cadherin junction integrity and evidence of TRITC-Dextran tracer leakage
quantified using systematic random sampling and unbiased ‘forbidden line’ counting principle to ensure that no
vascular profile and paracellular cleft were counted twice [11]. For sampling efficiency, a minimum of 200 vascular
profiles were counted from images per perfused placenta; c 600 vascular profiles were analysed for each experimental
condition. For HUVEC monolayers, junctional integrity was determined by counting the % of paracellular clefts
showing uniformVE-cadherin staining as a continuous thin line.Gaps in cell–cell adhesion regionswithVE-cadherin
negative cell edges were also counted. The % of cell–cell overlap showing thicker bands of VE-cadherin localization
was noted. For placental sections, the total percentage of vascular profiles showing disrupted junctional VE-cadherin
2766 c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
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(discontinuous staining or total loss) from paracellular clefts and associated tracer leakage (76 Mr Dextran-TRITC
visualized as peri-vascular ablumenal fluorescent puncta or ‘hotspots’) was counted [11]. All experimental images
from both HUVEC monolayers and placental sections were blinded to treatment regime before analyses.
Competitive binding ELISA
High-attachment 96-well ELISA plates (Corning, U.K.) were coated with recombinant Flt-1 overnight, and
co-incubatedwith biotinylated-VEGF-A165b (EC75), followed by non-biotinylated-VEGF-A165a (0–160 nM) or PlGF
(0–160 nM). Differences in VEGF binding to Flt-1 (n=12) were measured using streptavidin–HRP to biotin interac-
tions, using a Thermo Fluoroskan Ascent F2 fluorescence plate reader at an absorbance wavelength of 450 nm.
Statistical analyses
All statistical analysis was carried out using GraphPad Prism. Comparisons of means were made using one-way
ANOVA with Bonferroni’s post hoc test.
Results
VEGF-A165b inhibits VEGF-A165a-mediated permeability in HUVECs
Incubation of HUVEC monolayers with VEGF-A165a resulted in an increase in FITC–albumin tracer mass leak-
age over time (Figure 1A) compared with vehicle exposed cells. In contrast, incubation with VEGF-A165b in isola-
tion showed no change in FITC–albumin tracer mass permeate compared with vehicle over time. Co-incubation of
VEGF-A165b following 30 min of VEGF-A165a exposure resulted in the inhibition of VEGF-A165a-mediated increase
in FITC–albumin tracer mass leak (Figure 1A).
Exposure to PlGF alone also resulted in no change in FITC–albumin tracer mass permeate with time (Figure 1B).
Addition of PlGF after 30 min exposure to VEGF-A165a did not prevent the VEGF-A165a-mediated effects (see Figure
1B). Addition of PlGF alongside VEGF-A165b prevented VEGF-A165b-induced inhibition of VEGF-A165a-mediated
increase in FITC–albumin tracer mass leak (see Figure 1C). The calculated permeability values to FITC–albumin
tracer reflected these observations, whereby exposure to VEGF-A165a, but not VEGF-A165b or PlGF significantly
increased HUVEC monolayer permeability (P<0.001, Figure 1D). Similarly, VEGF-A165a-mediated permeability in-
crease was inhibited by VEGF-A165b (P<0.001) but not PlGF (P>0.05). PlGF co-incubation with VEGF-A165b abol-
ished the rescue of the latter from VEGF-A165a dependent increases in permeability (P<0.001) (Figure 1D).
VEGF-A165a but not VEGF-A165b or PlGF disrupts VE-cadherin junctions in
HUVECs
VE-cadherin immunostaining demonstrated the presence of positive junctional cell–cell overlap regions and thin
abutting junctions with continuous VE-cadherin staining (Figure 2) in control (vehicle only) experiments. Monolay-
ers treated with VEGF-A165a revealed observable endothelial junctional disruption after exposure (Figure 2B) with a
decrease in continuous thin junctions and increase in discontinuities or total loss of VE-cadherin staining in cell–cell
margins (described as gaps). This was not seen whenmonolayers were treated with VEGF-A165b (Figure 2C) or PlGF
(Figure 2D). Quantification (systematic random sampling) of the percentage of each type of VE-cadherin positive
regions (Figure 2H) showed that there was a statistically significant decrease in the number of thin junctions show-
ing continuous VE-cadherin occupancy (P<0.0001) after VEGF-A165a exposure. VE-cadherin discontinuity within
paracellular clefts increased with a significant increase in observable gaps (P<0.001). No significant change in both
percentage of disrupted junctions and % of continuous VE-cadherin junctions were found in VEGF-A165b or PlGF
experiments when compared with controls (P>0.05, Figure 2H).
VEGF-A165b prevented VEGF-A165a-mediated VE-cadherin junctional
disruption, which was inhibited by PlGF
VEGF-A165b (Figure 2E), but not PlGF (Figure 2F), was able to prevent VEGF-A165a-induced disruption of
VE-cadherin junctions after 2-h exposure. However, addition of PlGF in combination with VEGF-A165b (Figure 2G)
prevented the observed VEGF-A165b-mediated inhibition of VEGF-A165a-induced junctional disruption. Analysis of
percentage junctional integrity (Figure 2I) revealed a significant decrease in percentage of gaps after VEGF-A165b
co-incubation (P<0.0001) and an increase in percentage of thin continuous VE-cadherin junctions (P<0.01). No
significant changes in either percentage gap or continuous VE-cadherin AJ staining were observed after PlGF
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution License 4.0 (CC BY-NC-ND).
2767
Clinical Science (2017) 131 2763–2775
https://doi.org/10.1042/CS20171252
Figure 1. VEGF-A165b inhibits VEGF-A165a-mediated permeability increase in HUVEC monolayers
Graphs showing accumulation of FITC–albumin over time in transwell experiments (A, B and C) following exposure to VEGF-A165
isoforms, PIGF and vehicle only. Single VEGF additions were added at time = 0. Arrows indicate time of addition of VEGFs.
(A) VEGF-A165a (n=9, red trace) showing increase in tracer mass leakage over time compared with vehicle exposed cells (black).
VEGF-A165b (blue) shows similar leakage trace as vehicle. Addition of VEGF-A165b (n=11) following 30min of VEGF-A165a exposure
resulted in inhibition of this (green). (B) PlGF alone (n=7, magenta trace) did not increase tracer leakage, whilst co-incubation
with VEGF-A165a (orange) shows no inhibition of its activity (red). (C) Combination of all three growth factors (n=5, olive) shows
increased FITC–albumin solute flux, similar to VEGF-A165a alone. (D) Histograph showing the calculated permeability values of the
HUVEC monolayers. VEGF-A165a-mediated HUVEC permeability was inhibited by addition of VEGF-A165b but not PlGF (X-axis).
Co-incubation of PlGF with VEGF-A165b abolished the VEGF-A165b inhibition of VEGF-A165a-dependent increase in permeability
(***P<0.001 compared with vehicle); ND = not determined.
co-incubation (P>0.05). However, PlGF exposure in combination with VEGF-A165b abolished the VEGF-A165b in-
hibition of VEGF-A165a-mediated effects (P>0.05) (see Figure 2I).
PlGF competes with VEGF-A165b for binding to Flt-1
As the VEGF-A165b inhibition of VEGF-A165a mediated increased permeability was blocked by PlGF, which only
binds VEGFR1 (flt-1), we hypothesized that this could occur if VEGF-A165b was inhibiting VEGF-A165a by sig-
nalling through VEGFR1. VEGF-A165a and VEGF-A165b compete for R1 [28], so we therefore determined the effect
of PlGF on VEGF-A165b binding to VEGFR1 using an Fc-VEGFR1 chimaeric protein. Incubation of Fc-VEGFR1
with un-labelled human recombinant VEGF-A165b resulted in a concentration-dependent decrease in binding of
biotinylated-VEGF-A165b (EC75). Similarly, co-incubation with un-labelled PlGF resulted in an almost identical
concentration-dependent decrease in biotinylated-VEGF-A165b binding, with no significant difference in calculated
IC50 between the two proteins (P>0.05) (see Figure 3), thus suggesting that the inhibition of VEGF-A165a-mediated
permeability by VEGF-A165b could also be through its actions on VEGFR1.
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Figure 2. VEGF-A165b inhibits VEGF-A165a-induced disruption of VE-cadherin junctions
(A–D) Fluorescent micrographs showing VE-cadherin (green) immunolocalization in HUVEC monolayers treated with single ad-
ditions of VEGF splice variants, PIGF or vehicle. (A) In control monolayers (vehicle treated), VE-cadherin was visualized as thick
staining in cell–cell overlap regions (red arrow; thick junctions) and as continuous thin lines (yellow arrow) between cells. Some
cell–cell boundaries revealed discontinuous staining (white arrow) or extensive loss of VE-cadherin staining (asterisk). Nuclei were
stained with PI (red). (B) Monolayers treated with VEGF-A165a showed increased numbers of cell–cell junctions with loss of or
discontinuous VE-cadherin staining. This increase was not seen in monolayers exposed to VEGF-A165b (C) or PlGF (D). (E–G) Fluo-
rescent micrographs showing VE-cadherin immunostaining in HUVEC monolayers incubated with VEGF-A165a and VEGF-A165b (E)
or PlGF (F) or both VEGF-A165b + PlGF (G). VE-cadherin was found to show a continuous pattern of VE-cadherin staining similar to
control (see A) when co-incubated with VEGF-A165b (E). Disruption of VE-cadherin staining was observed in monolayers co-incu-
bated with PlGF (F). Incubation with all three growth factors (G) resulted in persistence of discontinuous junctional profiles (asterisk,
white arrows) seen for VEGF-A165a alone; bar = 50 μm. (H and I) Quantitative analyses of VE-cadherin junctional occupancy after
exposure to growth factors. (H) 2-h exposure to VEGF-A165a (n=5) resulted in an increase in the percentage of junctions showing
discontinuous or loss of junctional VE-cadherin (gaps, ***P<0.001) and decrease in the percentage of thin continuous VE-cadherin
junctions (****P<0.0001) when compared with vehicle only study group. Both VEGF-A165b (n=5) and PlGF (n=3) exposure did not
change percentage junction integrity when compared with vehicle (P>0.05). The number of overlapping cell–cell regions (thick) was
not found to be statistically different for the different treatments. (I) VEGF-A165b co-incubation with VEGF-A165a (n=5) decreased
the percentage of junctions showing gaps (****P<0.0001) and increased the percentage of continuous VE-cadherin thin junctions
(**P<0.01) compared with VEGF-A165a. This was not seen in the PlGF co-incubation experimental group (n=3). However, PlGF in
combination with VEGF-A165b (n=3) abolished VEGF-A165b inhibition of VEGF-A165a-mediated effects.
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
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Figure 3. PlGF competes with VEGF-A165b for binding to Flt-1
Co-incubation of Fc-VEGFR1 with un-labelled VEGF-A165b resulted in decreased binding of biotinylated-VEGF-A165b (n=4). PlGF
co-incubation equally inhibited biotinylated-VEGF-A165b binding to Flt-1 binding (n=4) (ns = P>0.05).
VEGF-A165a-mediated increased permeability and VE-cadherin disruption
are prevented by VEGF-A165b in the perfused human placental
microvascular bed
Using the more physiological dual-perfusion system, addition of growth factors to the fetal microcirculation of term
placental lobules resulted in observable differences in extravasation of TRITC-dextran (75 Mr) tracer (see Figure 4,
right panel). VEGF-A165a perfusions for 30 min resulted in a significant increase in percentage of vascular profiles as-
sociatedwith tracer leakage (71.2+− 13.8%, Figures 4 and 5) comparedwith control perfusions (30.2+− 4.4%; P<0.01).
In contrast, perfusions of VEGF-A165b saw no significant increase in percentage of leaky vessels (P>0.05) compared
with control perfusions. Addition of VEGF-A165b into the closed fetal circulation after a 30 min VEGF-A165a perfu-
sion period resulted in altered tracer leakage profile from that obtained with VEGF-A165a only perfusions. Vascular
profiles (9.4 +− 1.2%) were now found to be associated with peri-vascular ‘hotspots’ (P<0.05). This was not due to
temporal recovery, as addition of vehicle only for 30 min after VEGF-A165a perfusion showed no significant decrease
in profiles expressing hotspots (P>0.05). Subsequent immunohistochemical analyses of the same sections revealed
that tracer leakage matched disruption of VE-cadherin AJs (loss of VE-cadherin from paracellular clefts) (Figure
4, left panel). VEGF-A165a-perfusion of placental microvascular beds resulted in a 49.3% decrease in vascular pro-
files showing VE-cadherin at paracellular clefts (P<0.01), while perfusions of VEGF-A165b did not significantly alter
VE-cadherin positive vascular profiles (86.7 +− 0.8%) compared with controls (89.3 +− 2.3%) (P>0.05). Sequential
addition of VEGF-A165b to VEGF-A165a perfusions resulted in a recovery of junctional integrity with 81 +− 5% of
vascular profiles showing VE-cadherin at paracellular clefts (P<0.05; Figure 5).
Discussion
These studies are the first to show that the anti-angiogenic VEGF-A165b does not disturb the junctional occu-
pancy of VE-cadherin or induce paracellular tracer leakage in the human placental microvascular bed and HUVEC
monolayers. Indeed, VEGF-A165b (at a 2-fold concentration) can block/reverse VEGF-A165a-mediated increases in
feto-placental endothelial permeability to macromolecules (75 kDa) and loss of VE-cadherin from AJs. In these ex-
periments, PlGF did not affect endothelial integrity, VE-cadherin localization and permeability when added singly;
however, it could prevent the rescue of VEGF-A165a-mediated effects by VEGF-A165b.
The similarities between the observed induced changes in both fetal endothelial cell cultures and the more phys-
iological and complex perfused microvascular bed are re-assuring. Placental microvessels showed a robust response
to a 30 min perfusion of exogenous VEGF-A165a, with loss of VE-cadherin and increased vascular leak of 76 kDa
2770 c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution License 4.0 (CC BY-NC-ND).
Clinical Science (2017) 131 2763–2775
https://doi.org/10.1042/CS20171252
Figure 4. VEGF-A165b reverses VEGF-A165a-induced loss of junctional VE-cadherin and increased tracer leakage in perfused
placental microvessels
Representative fluorescent micrographs of villous biopsies taken from perfused placental microvascular beds. Left panel shows VE–
cadherin staining (FITC filter) whilst right panel shows the same image under TRITC filter to visualize any peri-vascular TRITC-dex-
tran ‘hotspots’; bar = 100 μm. (A) Image from control perfusion (vehicle only for 30 min) showing VE-cadherin positive microvas-
cular profiles within placental villous trees. (B) No peri-vascular hotspots can be seen in the same villous trees. (C) Image showing
a dramatic reduction in VE-cadherin positive vascular profiles following a 30 min perfusion with VEGF-A165a. (D) Numerous tracer
hotspots can now be seen trapped in the peri-vascular regions. (E) Image showing numerous VE-cadherin positive microvascular
profiles in villous trees following perfusion with VEGF-A165b for 30 min. (F) Note lack of or negligible presence of tracer hotspots in
these villi. (G) Image from placenta perfused with VEGF-A165a (30 min) followed by VEGF-A165b (30 min) and tracer. VE-cadherin
positive microvascular profiles are now a predominant feature, suggesting return of VE-cadherin to junctional regions. Concomi-
tantly, there is minimal peri-vascular tracer ‘hotspots’ (H).
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
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Figure 5. Quantitative analyses of VE-cadherin junctional occupancy and tracer leakage in perfused placental microvas-
cular beds
(A) Systematic counts (from 600 vascular profiles per experimental condition) revealed that in perfused placental microvascular
beds VEGF-A165a significantly decreased the percentage of VE-cadherin positive vascular profiles compared with VEGF-A165b or
vehicle only (***P<0.001). VEGF-A165b perfusion alone did not alter the % of VE-cadherin vascular profiles. In placentae where
VEGF-A165b was added after the 30 min VEGF-165a perfusion, % of VE-cadherin vascular profiles was found to be similar to that
of vehicle or VEGF-A165b perfusions. (B) The % of vessels showing extravasation of TRITC-dextran was significantly increased in
VEGF-A165a study group (**P<0.01), but not altered when placentae were perfused with VEGF-A165b when compared with vehicle
only. VEGF-A165b was able to reverse VEGF-A165a-mediated permeability effects – the % of vascular profiles with associated
peri-vascular hotspots was highly significantly reduced compared with VEGF-A165a perfusions (***P<0.001). *=significant; **=
very significant; ***=highly significant; ns=not significant.
dextrans. These changes were not induced when microvessels were perfused with VEGF-A165b; indeed this splice
variant could reverse the VEGF-A165a-induced changes both in the perfusion model and in transwell experiments.
The monolayer permeability results are similar to those recently described in lung pulmonary endothelial cells
[29], whereVEGF-A165a but notVEGF-A165bwas shown to increasemonolayer permeability and decrease junctional
integrity. However, they did not investigate the effect of PlGF on these cells.
The observed inability of either PlGF or VEGF-A165b to alter VE-cadherin occupancy and AJ integrity in hu-
man placental microvessels and fetal endothelial cells may be due to their lack of neuropilin-1 binding property
[22,26,30]. Neuropilin-1 is critical for VEGF-mediated endothelial permeability in human pulmonary endothe-
lial cells and for pulmonary vascular leaks in inducible lung-specific VEGF transgenic mice [22]. Stable trans-
fection of the neuropilin-1–VEGFR2 complex in endothelial cells resulted in decreased transendothelial resis-
tance in a dose-dependent fashion following addition of VEGF-A165a; this was not seen for single transfections of
VEGFR2 or neuropilin-1 alone. Moreover, VEGF-A165b prevents the formation of neuropilin–VEGFR2 complexes
by VEGF-A165a [31]. The reduction in VEGF-A165a-mediated enhanced permeability in our studies may be due to
competitive binding of VEGF-A165b to the VEGFR2 receptor [25]. KDR occupancy by VEGF-A165b may be fol-
lowed by internalization but not the subsequent neuropilin-1 dependent re-shuttling of KDR to the membrane sur-
face [32]. This therefore would rule out further VEGF-A165a binding and triggering of phosphorylation events that
lead to translocation of VE-cadherin from AJ domains. The recovery of junctional integrity seen in the sequential
VEGF-A165a + VEGF-A165b perfusions, but not in VEGF-A165a + vehicle perfusions argues that VEGF-A165b is act-
ing as an active signalling inhibitor. Our data allow one to hypothesize that the relative contributions of the two
different VEGF-A165 isoforms may be an important driver behind the different feto-placental vascular permeability
(and angiogenesis) observed for the different trimesters of pregnancy [9,10].
Plasma taken frompre-eclampticmothers has been shown to induce transient increases in permeability in amphib-
ian models, which was blocked by VEGF-A165b specific neutralizing antibodies, and receptor tyrosine inhibitors at
concentrations specific to VEGFR1 blockage [33]. This neutralizing antibody to VEGF-A165b was shown to prevent
the inhibition of VEGF-A165b-mediated blockade of VEGF-A165a-induced migration and cytoprotection of endothe-
lial cells [34] and anti-angiogenesis in peripheral vasculardisease [35]. This suggests that the pre-eclamptic plasmanot
only contained physiologically activeVEGF-A165b, but its action was incurred by altering the balance ofVEGF-A165b,
PlGF and VEGF-A165a, such thatVEGF-A165awas no longer able to induce the increase in permeability, potentially by
binding heterodimers of VEGF-A165b with either PlGF or VEGF-A165a. Such heterodimers are theoretically possible
but have not yet been clearly demonstrated.
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PIGF did not increase AJ disruption or permeability of the fetal human umbilical vein endothelial cells. PIGF-1,
but not PIGF-2, has been shown to stabilize VE-cadherin junctions after activation with VEGF in bovine retinal
endothelial cells and after intra-vitreal injections in mouse, during a critical window [36]. The isoform used here
was PlGF-2, which binds heparin and is therefore able to signal through VEGFR1 with heparin, indicating that
full signalling does require the heparin binding domains. The PlGF-mediated abolition of VEGF-A165b induced
reversal of VEGF-A165a-induced permeability was surprising. However, recent studies by Ganta et al. [37] have
shown that VEGF-A165b inhibits VEGF-A165a-mediated signalling in adipose endothelial cells through inhibiting
VEGFR1-mediated activation of the signal transducer and activator of transcription 3 (STAT3) pathway. It is there-
fore possible that VEGF-A165b binds VEGFR1, inhibiting STAT3 signalling. When PlGF binds VEGFR1, even if it
does not inhibit STAT3 signalling (or stimulate it), it prevents VEGF-A165b from inhibiting it, so VEGF-A165a would
then be at liberty to increase permeability. There are currently no studies identifying whether PlGF signals through
STAT3 or how it affects VEGF-A165a-mediated STAT3 signalling, but it would appear that such studies are warranted.
In our HUVEC studies, when PlGF was added in combination with VEGF-A165b, there was an abolition of the
VEGF-A165b-induced reversal of VEGF-A165a-induced permeability. Whilst it is well known that VEGF-A165a and
PIGF can compete forVEGF-R1 binding [38], in the present study we have also shown that incubation of Fc-VEGFR1
with un-labelled PlGF resulted in a concentration-dependent decrease in biotinylated-VEGF-A165b binding. Thus,
addition of PIGF may have resulted in release of both splice variants. The excess VEGF-A165a would then be at
liberty to increase permeability via KDR–neuropilin signalling. Hetero-dimerization of PIGF with VEGF-A165b
could further assist VEGF-A165a activity. Further studies are needed to understand the complex interplay be-
tween VEGF-A/PIGF and their receptors/co-receptors. Elucidation of the multiple signalling pathways, including
whether/where the VEGFR1-linked angiogenic signalling pathway interacts with the VEGFR2-linked phosphory-
lation events that lead to disruption of VE-cadherin junctions is needed to understand how placental/fetal barrier
function is regulated.
In summary, we have shown that VEGF-A165b is able to inhibit vascular permeability induced by VEGF-A165a
in vitro, and in human placenta ex vivo, and that this is interfered with by placental growth factor. These results
suggests that alterations in the ratio of these growth factors during normal placental development and in complicated
pregnancies such as pre-eclampsia and diabetes would influence VE-cadherin clustering in fetal vessels and therefore
placental barrier function, given that both the fetal endothelium and the syncytiotrophoblast act as resistance in series
to materno-fetal hydrophilic solute transport.
Clinical perspectives
• The anti-angiogenic VEGF-A165b isoform does not increase permeability in human placental mi-
crovessels or fetal endothelial cells.
• VEGF-A165b isoform can interrupt VEGF-A165a-induced permeability of feto-placental vessels.
• The interplay of the VEGF-A165 isoforms with PIGF suggests that the ratio of these three factors may
be important in determining the placental endothelial barrier and therefore fetal well-being in normal
and complicated pregnancies.
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